Studies on the mode of action of diphtheria toxin. VI. Site of the action of toxin in living cells.

Using the technique of radioautography, it has been shown that a probable maximum of only 25-50 molecules iodine-125-labeled toxin per cell is bound by human HeLa cells treated with approximately 10(7) molecules of toxin per cell, or just under one saturating dose. Radioautographs of sections from labeled cells locate most if not all of the toxin molecules fixed to the outer cell membrane. Under identical conditions far less label is taken up by mouse L cells. It is probable that the resistance of this species to diphtheria toxin can be accounted for in terms of the failure of mouse cells to bind the toxin protein. The irreversible inhibition of protein synthesis in a living cell culture by a few molecules of toxin located at the cell surface is discussed in relation to the known interaction between toxin, NAD, and transferase II in mammalian cell extracts.

Studies on the mode of action of diphtheria toxin. IV. Specificity of the cofactor (NAD) requirement for toxin action in cell-free systems.

The ability of a number of nucleotides related to NAD to replace NAD as cofactors for inhibition by diphtheria toxin of peptide bond formation has been examined. Neither NADH nor NADP are active. Of some 14 analogues closely related structurally to NAD that have been tested, only 3-thiocarboxamide pyridine-AD is as active as NAD itself. Replacement of the 3-carboxamide group on the pyridine ring by an acetyl group, or deamination of the purine ring, resulted in derivatives with reduced activity. The results were interpreted as suggesting that NAD and certain related nucleotides are capable of specific interaction with diphtheria toxin. Using the method of equilibrium dialysis, reversible binding of 1 mole of NAD per mole of toxin has been demonstrated. Toxoid does not interact with NAD.

Studies on the mode of action of diphtheria toxin. 3. Site of toxin action in cell-free extracts.

Extracts from HeLa cells treated with excess diphtheria toxin for several hours, until all protein synthesis has been arrested, are still able to stimulate the poly U-directed incorporation of phenylalanine into polypeptides at a moderate rate. Activity may be restored to normal levels or above by addition of a soluble enzyme fraction containing transferase II. Our results are in agreement with those of Collier who has recently shown that toxin inactivates transferase II in extracts from rabbit reticulocytes. We have further demonstrated that amino acid incorporation in extracts from intoxicated HeLa cells is limited by their transferase II content whereas, in extracts from normal cells, it is the ribosomes and to a lesser extent sRNA that are limiting. We have found that only soluble transferase II is inactivated by toxin; the ribosome-bound enzyme is resistant.

Studies on the mode of action of diphtheria toxin. V. Inhibition of peptide bond formation by toxin and NAD in cell-free systems and its reversal by nicotinamide.

Inhibition of soluble transferase II activity in cell-free systems by diphtheria toxin and NAD can be prevented or reversed in the presence of a sufficient concentration of nicotinamide. Quantitative studies on inhibition of peptide bond formation in cell-free extracts by toxin and NAD have indicated that two successive reversible reactions are involved. First, toxin and NAD interact mole for mole to form a relatively dissociable complex. This toxin-NAD complex then reacts with transferase II to form an enzymatically inactive product that is but slightly dissociated. In the presence of sufficient nicotinamide, however, the latter complex can be broken down to yield active transferase II once more. Based on the above model, an equation has been derived that accurately predicts the per cent inhibition of amino acid incorporation in cell-free systems at any given toxin and NAD level. The observed inhibition appears to be independent of the sensitivity to toxin of the cell species from which the extracts were derived, and depends only on the toxin and NAD concentrations. Although the model satisfactorily explains inhibition of peptide bond formation by toxin in cell-free systems, further assumptions are needed to explain how still lower concentrations of toxin are able to arrest protein synthesis completely in the living cell.

Studies on the mode of action of diphtheria toxin. VII. Toxin-stimulated hydrolysis of nicotinamide adenine dinucleotide in mammalian cell extracts.

When diphtheria toxin and NAD are added to soluble fractions containing aminoacyl transfer enzymes isolated from rabbit reticulocytes or from HeLa cells, free nicotinamide is released and, simultaneously, an inactive ADP ribose derivative of transferase II is formed. The reaction is reversible, and in the presence of excess nicotinamide, toxin catalyzes the restoration of aminoacyl transfer activity in intoxicated preparations. In living cultures of HeLa cells, the internal NAD concentration is sufficiently high to account for the rapid conversion, catalyzed by a few toxin molecules located in the cell membrane, of the entire cell content of free transferase II to its inactive ADP ribose derivative. Completely inactive ammonium sulfate fractions containing soluble proteins isolated from cells that have been exposed for several hours to excess toxin, can be reactivated to full aminoacyl transfer activity by addition of nicotinamide together with diphtheria toxin. Transferase II appears to be a highly specific substrate for the toxin-stimulated splitting of NAD and thus far no other protein acceptor for the ADP ribose moiety has been found.

Action of diphtheria toxin in the guinea pig.

The blood clearance and distribution in the tissues of (125)I after intravenous injection of small doses (1.5-5 MLD or 0.08-0.25 microg) of (125)I-labeled diphtheria toxin has been followed in guinea pigs and rabbits and compared with the fate of equivalent amounts of injected (125)I-labeled toxoid and bovine serum albumin. Toxoid disappeared most rapidly from the blood stream and label accumulated and was retained in liver, spleen, and especially in kidney. Both toxin and BSA behaved differently. Label was found widely distributed among all the organs except the nervous system and its rate of disappearance from the tissues paralleled its disappearance from the circulation. There was no evidence for any particular affinity of toxin for muscle tissue or for a "target" organ. Previous reports by others that toxin causes specific and selective impairment of protein synthesis in muscle tissue were not confirmed. On the contrary, both in guinea pigs and rabbits, a reduced rate of protein synthesis was observed in all tissues that had taken up the toxin label. In tissues removed from intoxicated animals of both species there was an associated reduction in aminoacyl transferase 2 content. It is concluded that the primary action of diphtheria toxin in the living animal is to effect the inactivation of aminoacyl transferase 2. The resulting inhibition in rate of protein synthesis leads to morphologic damage in all tissues reached by the toxin and ultimately to death of the animal.

Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins.

The isolation of a new type of mutant Corynephage beta, which carries a missense mutation in the structural gene for diphtheria toxin synthesis is described. The lysogenic C7(8)(beta(197))(tox-crm+) strain of Corynebacterium diphtheriae produces a nontoxic, extracellular protein of molecular weight 62,000. This protein is immunologically indistinguishable from toxin itself but inhibits the action of toxin on HeLa cells, probably by competing for attachment sites on the cell membrane. In contrast to fragment A derived from diphtheria toxin, fragment A(197) is unable to catalyze the inactivation of eucaryotic polypeptidyl-transfer RNA-transferase II. When mixtures of the two nontoxic mutant proteins, enzymically active crm(45) protein and enzymically inactive crm(197) protein, are subjected to mild treatment with trypsin in the presence of a thiol and then allowed to reoxidize after dialysis to remove excess thiol, "diphtheria toxin" is reconstituted in high yield.

Antibodies to pneumococcal polysaccharides: relation between binding and electrophoretic heterogeneity.

Antibodies to type III and type VIII pneumococcal polysaccharides were examined with respect to ligand binding and electrophoretic heterogeneity. Both antibodies showed apparent binding homogeneity, although multiple light chain and heavy chain electrophoretic species were demonstrated.

Monoclonal antibody analysis of diphtheria toxin--II. Inhibition of ADP-ribosyl-transferase activity.

Monoclonal antibodies directed against the enzymatically active A-fragment of diphtheria toxin were used to investigate further the structure-function relationships within fragment A. Of 16 such antibodies, all but two were directed against epitopes located within the carboxy-terminal 30-40 amino acids of fragment A. Interestingly, the antibodies recognize several epitopes in this small region and varied considerably in their effects on toxin functions. With regard to their effects on the enzymatic activity of fragment A, three types of antibodies were found: (1) antibodies which bind fragment A but fail to inhibit its ADP-ribosyltransferase activity, (2) antibodies which completely inhibit enzyme activity, and (3) antibodies which interact with fragment A to yield antigen-antibody complexes of diminished activity. The results are consistent with location of the catalytic center of fragment A within its carboxy-terminal ca 4000 dalton region.

Transport of diphtheria toxin A fragment across the plasma membrane.

The 60,000-dalton diphtheria toxin molecule is synthesized and released from the bacteria as a single polypeptide chain which may be subdivided into three functional regions of approximately equal length. There is an enzymically active 21,150-dalton A fragment extending from the N-terminal glycine residue to the first of the two disulfide bridges. This hydrophilic, negatively charged polypeptide must cross the plasma membrane of the target cell and reach the cytoplasm in order to inactivate EF-2 by ADP-ribosylation and thereby block protein synthesis. There is a C-terminal postiviely charged polypeptide sequence of 10,000--20,000 daltons which interacts with specific receptors present on the membranes of sensitive cells and which includes the second cystine disulfide. Between these two hydrophilic regions there is an hydrophobic zone which, when "unmasked," is capable of binding about 44 molecules of the nonionic detergent Triton X-100 and readily becomes inserted into membrane vesicles. It is suggested that the entry process involves an initial reversible interaction with membrane receptors, followed by an irreversible process in which the C-terminal region is released by a proteolytic cleavage, thus permitting the hydrophobic portion of the molecule to enter the lipid bilayer and form a channel through which the A fragment is drawn in an extended form to reach the cytoplasm.

On the alleged high sensitivity of mouse Ehrlich-Lettre ascites tumor cells to diphtheria toxin.

It was recently reported by Iglewski and Rittenberg in THESE PROCEEDINGS (71, 2707-2710, 1974) that low doses of purified diphtheria toxin inhibit protein synthesis in mouse Ehrlich-Lettre ascites carcinoma cells cultured in vitro. These observations could not be confirmed by us nor could the authors' further claim that toxin can cause regression of well-established ascites tumors in preimmunized mice be confirmed. Although temporary regression of such tumors can be demonstrated in unimmunized mice following intraperitoneal injection of diphtheria toxin, the amounts of toxin required are high and approach the lethal dose. About the same amount of CRM45, a tox gene product serologically related to diphtheria toxin but only 1/10,000th as toxic for guinea pigs, will also cause temporary regression in tumor-bearing mice.

Interaction of diphtheria toxin with mammalian cell membranes.

Uptake of 125I-labeled diphtheria toxin and serologically related proteins by a sensitive human HeLa cell line and by a resistant mouse L929 cell line has been studied. The evidence suggests that there is an initial rapid reaction between a recognition site present on the toxin Fragment B and specific plasma membrane receptors on the sensitive cell (there are approximately 4000/HeLa cell). This initial interaction is followed by a slow irreversible process during which there is a major conformational alteration of the toxin molecule causing the enzymically active 22,000-dalton Fragment A to become exposed to the cytosol. We suggest that it is at this point that cleavage of the NH2-terminal disulfide bond occurs leading to release of Fragment A into the cytoplasm. The toxin Fragment B remains attached to the membrane, probably formed in a complex with receptor, and blocks entry of additional toxin molecules through the same site. Specific membrane receptors are lacking from mouse cells. Both HeLa cells and L929 cells internalize toxin, related nontoxic proteins, and inert molecules such as inulin nonspecifically into endocytotoc vesicles. At 30 degrees the bulk internalization of extracellular fluid is about 1.2% of their cell volume per h for both cell lines. Fragment A does not traverse the plasma membrane by a mechanism that depends on endocytosis. The interaction of diphtheria toxin with the sensitive cell membrane is discussed in relation to other protein toxins and certain glycopeptide tropic hormones in which relatively large, hydrophilic polypeptide fragments or subunits are presumed to traverse the target cell plasma membrane and reach the cytoplasm in biologically active form.

Kinetics of adenosinediphosphoribosylation of elongation factor 2 in cells exposed to diphtheria toxin.

When susceptible cells are exposed to diphtheria toxin (Mr, 62,000) the N-terminal 21,150-dalton A fragment of toxin reaches the cytoplasm, where it catalyzes the transfer of adenosinediphosphoribose from nicotinamide adenine dinucleotide to elongation factor 2 (EF2). Adenosinediphosphoribose-EF2 is inactive, so that protein synthesis is blocked. Using a simple, rapid assay for the amount of adenosinediphosphoribosylatable EF2 in unfractionated lysates of cultured cells we have followed the kinetics of inactivation of EF2 in CV-1 and BHK cells exposed to diphtheria toxin. With both cell lines a lag was observed between the addition of toxin to the cells and the adenosinediphosphoribosylation of EF2. The lag decreased with increasing toxin concentration until a limiting value of about 12 min was reached. The rate of adenosinediphosphoribosylation of EF2 after the lag was 10 to 20 times more rapid in CV-1 cells than in BHK cells exposed to the same toxin concentration. The concentration of fragment A active in the cytoplasm of toxin-treated cells was estimated from the rate of adenosinediphosphoribosylation observed. Comparison of these estimates with data from studies of binding of 125I-toxin to cells suggests that the fragment A of only a minor fraction of toxin molecules bound to cell surface receptors reaches the cytoplasm and participates in the inactivation of EF2. A model summarizing our current views on the process by which fragment A enters cells is presented.

Studies on the molecular epidemiology of diphtheria.

DNA was extracted from toxigenic and nontoxigenic (tox+ and tox-) diphtheria bacilli isolated during a carrier survey that followed recovery of a tox+ Corynebacterium diphtheriae mitis from a baby with membranous tonsillitis. The electrophoretic gel patterns of restriction enzyme digests were indistinguishable from one another. They were, however, readily distinguishable from similar gels of DNAs extracted from diphtheria bacilli associated with outbreaks elsewhere. Hybridisation of a labelled nick-translated corynephage-beta c-DNA probe to nitrocellulose blots of these gels occurred only to blots from tox+ strains. Other hybridisation studies showed that all of seven strains, each isolated from a diphtheria case or carrier in a different part of the world, carried a prophage with DNA closely related to phage beta tox+. When an individual carrying a tox+ diphtheria bacillus arrives in an immunised community, spread of the tox gene to other individuals may be via phage conversion of tox- C diphtheriae already prevalent among the nasopharyngeal bacterial flora of the local populace, rather than by colonisation with the tox+ strain itself.

Role of a luciferin-binding protein in the circadian bioluminescent reaction of Gonyaulax polyedra.

A luciferin-binding protein (LBP), which binds and protects from autoxidation the substrate of the circadian bioluminescent reaction of Gonyaulax polyedra, has been purified to near homogeneity. The purified protein is a dimer with two identical 72-kDa subunits, and an isoelectric point of 6.7. LBP is a major component of the cells, comprising about 1% of the total protein during the night phase, but drops to only about 0.1% during the day. The luciferin is protected from autoxidation by binding to LBP, and one luciferin is bound per dimer at alkaline pH (Ka approximately 5 x 10(7) M-1). The protein undergoes a conformational change with release of luciferin at pH values below 7, concurrent with an activation of Gonyaulax luciferase. LBP thus has a dual role in the circadian bioluminescent system.

Properties and cellular localization of a luciferin binding protein in the bioluminescence reaction of Gonyaulax polyedra.

A luciferin binding protein LBP involved in the bioluminescence reaction of Gonyaulax polyedra was purified and used for antibody production. Luciferin bound to LBP is fluorescent and can be used as a marker in living cells, allowing the localization of LBP in cortical organelles to be visualized. In cell sections, the same peripheral localization was observed using anti-LBP and immunofluorescence microscopy. The amount of LBP is ten-fold greater from cells from in night phase compared to those from in day phase, as determined both by immunoblots of cell extracts, and in vivo fluorescence. These changes correlate with the circadian changes in bioluminescence of living cells.